KRAS Mutation Detection Kit (Based on real-time PAP nucleic acid amplification)

About 30% of various cancer patients harbor KRAS somatic mutations, such as 30-40% in colorectal cancer, 2-10% in non-small cell lung cancer and 90% in pancreatic cancer. In addition, 90% of all the mutations concentrate on 12 and 13 codons in exon 2. 

Importantly, cancer patents with KRAS mutations do not respond well to tyrosine kinase inhibitor therapy of Iressa, Tarceva, Erbitux and Vectibix, indicating the impact of the mutation status in therapy selection.  

Learn More